Skip to main content
Clinical Trials/NCT05109143
NCT05109143
Completed
Not Applicable

Efficacy of Rectal Indomethacin in Prevention of Post-operative Pancreatitis After Pancreaticoduodenectomy - a Randomized Controlled Trial

Institute of Liver and Biliary Sciences, India1 site in 1 country44 target enrollmentOctober 17, 2020

Overview

Phase
Not Applicable
Intervention
Standard Medical Treatment
Conditions
Pancreatoduodenectomy
Sponsor
Institute of Liver and Biliary Sciences, India
Enrollment
44
Locations
1
Primary Endpoint
Post-operative Pancreatitis
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Pancreatico-duodenectomy is one of the commonly performed procedure for periampullary/distal cholangio/head of pancreas carcinoma. Post operative pancreatitis is an emerging concept, recently being studied as one of the most important contributing factor of Post-operative pancreatic fistula, which is one of the major complication of pancreatoduodenectomy. Rectal indomethacin, a type of non-steroidal anti-inflammatory drug, when given in a single dose has been shown to prevent pancreatitis in patients undergoing ERCP. In this study, we will be administering rectal indomethacin at the time of induction of anesthesia to the experimental arm of the study and compare the results in terms of incidence of post-operative pancreatitis in the two groups.

Registry
clinicaltrials.gov
Start Date
October 17, 2020
End Date
May 31, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • All consenting adults planned to undergo pancreatoduodenectomy,

Exclusion Criteria

  • allergic reactions to NSAIDs
  • internal hemorrhoids
  • anti-platelet medications

Arms & Interventions

Group B

Standard Medical Treatment

Intervention: Standard Medical Treatment

Group A

Will be administered 100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia with Standard Medical Treatment

Intervention: Indomethacin suppository

Group A

Will be administered 100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia with Standard Medical Treatment

Intervention: Standard Medical Treatment

Outcomes

Primary Outcomes

Post-operative Pancreatitis

Time Frame: first 30 days following pancreatoduodenectomy

Secondary Outcomes

  • intra-abdominal abscess(first 30 days following pancreatoduodenectomy)
  • Length of ICU stay(First 30 days following pancreatoduodenectomy)
  • Post-operative Pancreatic Fistula(first 30 days following pancreatoduodenectomy)
  • delayed gastric emptying(First 30 days following pancreatoduodenectomy)
  • Length of hospital stay(First 30 days following pancretoduodenectomy)
  • risk factors of post-operative pancreatitis(first 30 days following pancreatoduodenectomy)

Study Sites (1)

Loading locations...

Similar Trials